Faeth Therapeutics Inc (FTH)

$14.53 +0.68 (4.91%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 155,200
Avg Vol 44,408
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 53%
Beta N/A
Analysts Strong Buy
Price Target N/A
Latest News on FTH
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Jun 15, 2026, 8:10 AM EDT - 2 days ago

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

SNSE

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2026, 4:00 PM EDT - 12 days ago

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SNSE

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026, 7:30 AM EDT - 4 weeks ago

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSE

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

May 5, 2026, 7:30 AM EDT - 6 weeks ago

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

SNSE

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSE

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

SNSE

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Feb 18, 2026, 8:00 AM EST - 4 months ago

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

SNSE

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Jan 7, 2026, 8:00 AM EST - 5 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

SNSE

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 7:30 AM EST - 7 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

SNSE

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 30, 2025, 9:00 AM EDT - 8 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

SNSE

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSE

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 23, 2025, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSE

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

SNSE

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SNSE

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jul 30, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

SNSE

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Jun 13, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

SNSE

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

SNSE

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SNSE

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

SNSE

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

SNSE

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

SNSE

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

SNSE

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

SNSE

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SNSE

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

SNSE

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

SNSE

Sensei Biotherapeutics to Present at Upcoming Conferences

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

SNSE

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 6, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

SNSE

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

SNSE

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 23, 2024, 5:10 PM EDT - 2 years ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

SNSE

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 10, 2024, 11:45 AM EDT - 2 years ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

SNSE

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

SNSE

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

SNSE

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

SNSE

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Apr 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

SNSE

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 22, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

SNSE

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

SNSE

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

SNSE

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

SNSE

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

SNSE

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

SNSE

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

SNSE

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

SNSE

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

SNSE

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

SNSE

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Sep 13, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

SNSE

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 30, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

SNSE

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 3, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

SNSE

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Aug 2, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

SNSE

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 13, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

SNSE